Belite Bio hits go on IPO to fund late-phase vision loss clinical trials

Belite Bio wants public investors to bankroll late-phase clinical trials of a treatment for certain causes of blindness. With one study underway and another on the horizon, the San Diego-based biotech has filed the paperwork for a Nasdaq IPO.